[1]
|
Wingerchuk, D.M. and Weinshenker, B.G. (2003) Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology, 60, 848-853.
doi:10.1212/01.WNL.0000049912.02954.2C
|
[2]
|
Carroll, W.M. and Fujihara, K. (2010) Neuromyelitis optica. Current Treatment Options in Neurology, 12, 244-255. doi:10.1007/s11940-010-0071-z
|
[3]
|
Marignier, R., Nicolle, A., Watrin, C., et al. (2010) Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain, 133, 2578-2591.
doi:10.1093/brain/awq177
|
[4]
|
Sospedra, M. and Martin, R. (2005) Immunology of multiple sclerosis. Annual Reviews of Immunology, 23, 683-747.doi:10.1146/annurev.immunol.23.021704.115707
|
[5]
|
Kerlero de Rosbo, N., Honegger, P., Lassmann, H., et al. (1990) Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. Journal of Neurochemistry, 55, 583-587. doi:10.1111/j.1471-4159.1990.tb04173.x
|
[6]
|
Stefferl, A., Brehm, U., Storch, M., et al. (1999) Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the resistant. Journal of Immunology, 163, 40-49.
|
[7]
|
Pittock, S.J., Reindl, M., Achenbach, S., et al. (2007) Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: Frequency, stability and clinicopathologic correlations. Multiple Sclerosis Journal, 13, 7-16. doi:10.1177/1352458506072189
|
[8]
|
Wang, H., Munger, K.L., Reindl, M., et al. (2008) Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology, 71, 1142-1146.
|
[9]
|
Kezuka, T., Usui, Y., Yamakawa, N., et al. (2012) Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. Journal of Neuro-Ophthalmology, 32, 107-110. doi:10.1097/WNO.0b013e31823c9b6c
|
[10]
|
Wingerchuk, D.M., Lennon, V.A., Pittock, S.J., et al. (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology, 66, 1485-1489.
doi:10.1212/01.wnl.0000216139.44259.74
|
[11]
|
Johns T.G. and Bernard C.C. (1999) The structure and function of myelin oligodendrocyte glycolprotein. Journal of Neurochemistry, 72, 1-9.
doi:10.1111/j.1471-4159.1999.tb11579.x
|
[12]
|
Khalis, M., Reindl, M., Lutterotti, A., et al. (2006) Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycolprotein: Influence of relapses and immunomodulatory treatments. Journal of Neuroimmunology, 174, 147-156.
|
[13]
|
Berger, T., Rubner, P., Schautzer, F., et al. (2003) Anti-myelin antibodies as a predictor of clinically definitive multiple sclerosis after a first demyelinating event. The New England Journal of Medicine, 349, 139-145.
doi:10.1056/NEJMoa022328
|
[14]
|
Tomassini, V., De Giglio, L., Reindl, M., et al. (2007) Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Multiple Sclerosis Journal, 13, 1086-1094. doi:10.1177/1352458507077622
|
[15]
|
Rauer, S., Euler, B., Reindl, M. and Berger, T. (2006) Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. Journal of Neurology, Neurosurgery & Psychiatry, 77, 739-742.
doi:10.1136/jnnp.2005.077784
|
[16]
|
Kuhle, J., Pohl, C., Mehling, M., et al. (2007) Lack of association between antimyelin antibodies and progresssion to multiple sclerosis. The New England Journal of Medicine, 356, 371-378. doi:10.1056/NEJMoa063602
|
[17]
|
Lim, E.T., Berger, T., Reindl, M., et al. (2005) Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Multiple Sclerosis, 11, 492-494.
|
[18]
|
Pelayo, R., Tintoré, M., Montalban, X., et al. (2007) Anti-myelin antibodies with no progression to multiple sclerosis. The New England Journal of Medicine, 356, 426-428.
doi:10.1056/NEJMc062467
|
[19]
|
Haase, C.G. and Schmidt, S. (2001) Detection of brain-specific autoantibodies to myelin oligodendrocyte glycolprotein, S100β and myelin basic protein in patients with Devic’s neuromyelitis optica. Neuroscience Letters, 307, 131-133. doi:10.1016/S0304-3940(01)01949-8
|
[20]
|
Correale, J. and Fiol, M. (2004) Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology, 63, 2363-2370.
doi:10.1212/01.WNL.0000148481.80152.BF
|
[21]
|
Alves-Leon, S.V., Pimentel, M.L., Sant’Anna, G., et al. (2008) Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. Arquivos de Neuro-Psiquiatr, 66, 678-684.
doi:10.1590/S0004-282X2008000500013
|
[22]
|
Kahlenberg, J.M. (2011) Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjögren’s syndrome. Seminars in Arthritis and Rheumatism, 40, 343-348. doi:10.1016/j.semarthrit.2010.05.005
|
[23]
|
Pittock, S.J., Lennon, V.A., De Seze, J., et al. (2008) Neuromyelitis optica and non-organ-specific autoimmunity. Archives of Neurology, 65, 78-83.
doi:10.1001/archneurol.2007.17
|
[24]
|
Takano, R., Misu, T., Takahashi, T., et al. (2010) Astrocytic damage is far more severe than demyelination in NMO. Neurology, 75, 208-216.
doi:10.1212/WNL.0b013e3181e2414b
|
[25]
|
Marignier, R., Giraudon, P., Vukusic, S., et al. (2010) Anti-aquaporin-4 antibodies in Devic’s neuromyelitis optica: Therapeutic implications. Therapeutic Advances in Neurological Disorders, 3, 311-321.
doi:10.1177/1756285610382478
|